An atlas of common Salmonella serotypes from routinely notified human cases in the Northern Territory of Australia, 2005-2024 [0.03%]
2005-2024年澳大利亚北部 Territories 各种常见沙门氏菌血清型图谱（基于常规报告的人类病例）
Anthony Draper,Martyn Kirk,Samantha Colquhoun et al.
Anthony Draper et al.
Salmonella infections cost Australian society an estimated 140 million Australian Dollars (AUD) per year circa 2019. Salmonellosis is caused by Salmonella enterica, with over 2,500 serotypes of S. enterica identified. Knowledge of the epide...
Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025 [0.03%]
澳大利亚脑膜炎监测报告：2025年10月1日至12月31日报告期
Monica Lahra,Siobhan Hurley,Tiffany Hogan
Monica Lahra
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques...
Australian Gonococcal Surveillance Program, 1 October to 31 December 2025 [0.03%]
2025年10月1日至12月31日澳大利亚淋病监测项目报告
Monica Lahra,Siobhan Hurley,Sebastiaan Van Hal et al.
Monica Lahra et al.
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal S...
An outbreak of Salmonella Waycross related to sandpit contamination in a Gold Coast childcare centre, Queensland, Australia, 2024 [0.03%]
2024年澳大利亚昆士兰州黄金海岸某育儿中心因沙坑污染引发的韦克萨氏沙门氏菌疫情
Heshani Rupasinghe,Kate Alexander,Fiona May et al.
Heshani Rupasinghe et al.
Salmonella Waycross is a serovar with limited published literature on its reservoirs and epidemiology. In April 2024, the Gold Coast Public Health Unit (GCPHU) identified an outbreak of S. Waycross at a childcare centre in Queensland, Austr...
Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2025 [0.03%]
澳大利亚脑膜炎监测报告：2025年7月1日至9月30日期间
Monica Lahra,Siobhan Hurley,Tiffany Hogan
Monica Lahra
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques...
An outbreak of measles linked to healthcare services in Far North Queensland, 2025 [0.03%]
2025年北昆士兰医疗保健服务机构关联的麻疹暴发事件
Tonia Marquardt,Simon Smith,Juliet Esmonde et al.
Tonia Marquardt et al.
In September 2025, Cairns experienced its largest measles outbreak since 1997. An imported case from Indonesia subsequently transmitted to 11 secondary cases, including four hospital staff. No further transmission was identified despite ide...
ATAGI Targeted Review 2024: Immunisation strategies for prevention and control of respiratory syncytial virus disease in Australia [0.03%]
2024年澳大利亚呼吸道合胞病毒疾病预防和控制免疫策略的ATAGI定向审查
Chisato Imai-Boulter,Jean Li-Kim-Moy,Jocelynne McRae et al.
Chisato Imai-Boulter et al.
Respiratory syncytial virus (RSV) causes lower respiratory tract infection and severe disease, particularly in infants, and is increasingly recognised as a cause of major morbidity and mortality in the elderly. Several new vaccines aim to a...
Katrina Nicolopoulos,Saskia van der Kooi,Clayton Chiu et al.
Katrina Nicolopoulos et al.
The Australian Technical Advisory Group on Immunisation (ATAGI) 2025 Annual Statement on Immunisation is the fifth publication in this series. It highlights the key successes, trends and challenges in the use of vaccines and control of vacc...
Katrina Nicolopoulos,Catherine Tran,Clayton Chiu et al.
Katrina Nicolopoulos et al.
The Australian Technical Advisory Group on Immunisation (ATAGI) 2024 Annual Statement on Immunisation is the fourth publication in this series. It highlights the key successes, trends and challenges in the use of vaccines and control of vac...
Infant respiratory syncytial virus (RSV) immunisation coverage in an Australian regional area, 1 May 2024 - 31 October 2025 [0.03%]
2024年5月1日至2025年10月31日澳大利亚地区婴儿呼吸道合胞病毒(RSV)免疫接种覆盖率
William Roughan,Brett Cavanagh-Ochiai,Donna Barnekow et al.
William Roughan et al.
The recent introduction in Australia of respiratory syncytial virus (RSV) immunisations - nirsevimab (neonatal) and Abrysvo (antenatal) - offers potential to reduce the RSV burden in infants. A retrospective cohort study included all infant...